Most Popular Articles : HemaSphere

Journal Logo

Most Popular Articles

The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action

Fioredda, Francesca; Skokowa, Julia; Tamary, Hannah; More

HemaSphere. 7(4):e872, April 2023.

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

Verkleij, Christie P.M.; Frerichs, Kristine A.; Broekmans, Marloes E.C.; More

HemaSphere. 7(5):e881, May 2023.

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET

Wille, Kai; Brouka, Maja; Bernhardt, Johannes; More

HemaSphere. 7(5):e882, May 2023.

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Østergaard, Anna; Enshaei, Amir; Pieters, Rob; More

HemaSphere. 7(5):e875, May 2023.

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

Valent, Peter; Akin, Cem; Hartmann, Karin; More

HemaSphere. 5(11):e646, November 2021.

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

Dimopoulos, Meletios A.; Moreau, Philippe; Terpos, Evangelos; More

HemaSphere. 5(2):e528, February 2021.

An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA

Rejeski, Kai; Greco, Raffaella; Onida, Francesco; More

HemaSphere. 7(5):e889, May 2023.

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab

Rodier, Cyrielle; Kanagaratnam, Lukshe; Morland, David; More

HemaSphere. 7(5):e861, May 2023.

Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance

Schutgens, Roger E.G.; Jimenez-Yuste, Victor; Escobar, Miguel; More

HemaSphere. 7(6):e900, June 2023.

Genetic Subtypes and Outcome of Patients Aged 1 to 45 Years Old With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial

Norén-Nyström, Ulrika; Andersen, Mette K.; Barbany, Gisela; More

HemaSphere. 7(5):e883, May 2023.

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

Baliakas, Panagiotis; Espinet, Blanca; Mellink, Clemens; More

HemaSphere. 6(4):e707, April 2022.

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet

Itzykson, Raphael; Fenaux, Pierre; Bowen, David; More

HemaSphere. 2(6):e150, December 2018.

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi

Zamprogna, Giulia; Frustaci, Anna Maria; Travi, Giovanna; More

HemaSphere. 7(5):e880, May 2023.

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

Gaidzik, Verena I.; Paschka, Peter; Schlenk, Richard F.; More

HemaSphere. 7(5):e877, May 2023.

Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria

Tometten, Mareike; Kirschner, Martin; Meyer, Robert; More

HemaSphere. 7(5):e874, May 2023.

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report

Rodeghiero, Francesco; Pabinger, Ingrid; Ragni, Margaret; More

HemaSphere. 3(5):e286, October 2019.

Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia

Palmi, Chiara; Bresolin, Silvia; Junk, Stefanie; More

HemaSphere. 7(6):e892, June 2023.

A Decision-tree Approach to Stratify DLBCL Risk Based on Stromal and Immune Microenvironment Determinants

Zaccaria, Gian Maria; Vegliante, Maria Carmela; Mezzolla, Giuseppe; More

HemaSphere. 7(4):e862, April 2023.

Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing

Meyers, Sarah; Alberti-Servera, Llucia; Gielen, Olga; More

HemaSphere. 6(4):e700, April 2022.

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Tettero, Jesse M.; Freeman, Sylvie; Buecklein, Veit; More

HemaSphere. 6(1):e676, January 2022.

P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA-DIRECTED CAR-T CELL THERAPY MANUFACTURED USING THE T-CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)

Sperling, A. S.; Nikiforow, S.; Derman, B.; More

HemaSphere. 6:1329-1330, June 2022.

Autoimmune Lymphoproliferative Syndrome (ALPS) Disease and ALPS Phenotype: Are They Two Distinct Entities?

Palmisani, Elena; Miano, Maurizio; Grossi, Alice; More

HemaSphere. 7(3):e845, March 2023.

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Ghia, Paolo; Pluta, Andrzej; Wach, Małgorzata; More

HemaSphere. 6(12):e801, December 2022.

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Rejeski, Kai; Blumenberg, Viktoria; Iacoboni, Gloria; More

HemaSphere. 7(4):e858, April 2023.

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Tun, Aung M.; Wang, Yucai; Matin, Aasiya; More

HemaSphere. 7(4):e869, April 2023.

The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice Paper

Roy, Noémi B. A.; Da Costa, Lydie; Russo, Roberta; More

HemaSphere. 6(6):e739, June 2022.

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS

Touzeau, C.; Krishnan, A.; Moreau, P.; More

HemaSphere. 6:85-86, June 2022.

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Gotti, Manuel; Sciarra, Roberta; Pulsoni, Alessandro; More

HemaSphere. 7(4):e837, April 2023.

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

Argnani, Lisa; Broccoli, Alessandro; Pellegrini, Cinzia; More

HemaSphere. 6(12):e798, December 2022.

Recommendations for Pregnancy in Rare Inherited Anemias

Taher, Ali T.; Iolascon, Achille; Matar, Charbel F.; More

HemaSphere. 4(4):e446, August 2020.

S196: ROPEGINTERFERON ALFA-2B ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES

Gisslinger, H.; Klade, C.; Georgiev, P.; More

HemaSphere. 6:97-98, June 2022.

Hematopoietic Cell Autonomous Disruption of Hematopoiesis in a Germline Loss-of-function Mouse Model of RUNX1-FPD

Ernst, Martijn P. T.; Pronk, Eline; van Dijk, Claire; More

HemaSphere. 7(2):e824, February 2023.

S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Dickinson, M.; Kwon, M.; Briones, J.; More

HemaSphere. 6:113-114, June 2022.

Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases

Galusic, Davor; Basic-Kinda, Sandra; Pijuk, Andela; More

HemaSphere. 6(12):e807, December 2022.

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

Voltin, Conrad-Amadeus; Gödel, Philipp; Beckmann, Laura; More

HemaSphere. 7(1):e817, January 2023.

S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY

Rives, S.; Maude, S. L.; Hiramatsu, H.; More

HemaSphere. 6:13-14, June 2022.

S216: CLINICAL ACTIVITY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE 1, OPEN-LABEL STUDY

Michot, J.-M.; Chavez, J. C.; Carpio, C; More

HemaSphere. 6:117-118, June 2022.

Show: